BIO-Europe Spring® 2017: Newron CEO on Xadago and upcoming pipeline milestones

April 11, 2017

Newron CEO Stefan Weber discusses the company's Parkinson's therapy, Xadago (safinamide), on the eve of its US market approval during the recent BIO-Europe Spring partnering conference. Newron, a clinical-stage biopharma company listed on the Swiss Exchange, is focused on the development of novel therapies for patients with diseases of the central nervous system. As well as Xadago—developed in partnership with Zambon, which holds global marketing rights to the product with the exception of Asia—Newron has three other clinical assets in its pipeline. Its most advanced is sarizotan, a serotonin 1A (5-HT1A) receptor agonist in development for the treatment of orphan disease Rett syndrome.

 

Click here for more coverage of the activities held during BIO-Europe Spring

Previous Video
BIO-Europe Spring® 2017: Biomunex CSO defines lead compounds, early R&D plans
BIO-Europe Spring® 2017: Biomunex CSO defines lead compounds, early R&D plans

During BIO-Europe Spring 2017 in Barcelona, Eugene Zhukovsky, chief scientific officer at Biomunex speaks t...

Next Video
BIO-Europe Spring® 2017: Chronic constipation device impresses judges in startup competition
BIO-Europe Spring® 2017: Chronic constipation device impresses judges in startup competition

usMIMA is a team of scientists and engineers that has developed a solution for chronic constipation. The gr...